Treximet Migraine Brain Imaging Research Study

NCT ID: NCT01112553

Last Updated: 2012-11-01

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 2 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2012-10-31

Brief Summary

We are looking for volunteers who suffer from acute migraine (<14 episodes per month) to participate in a 2-visit brain imaging research study. The goal of the study is to observe the effect of acute administration of Treximet during a migraine episode on the pain pathways of the migraine brain. Visit 1 will consist of 1 hour, where participants will be signing the informed consent form, completing questionnaires, meeting with the study physician, and having QST (sensory testing to determine individual pain thresholds to a heat stimulus) performed. Visit 2 will occur during a migraine episode. Volunteers will be asked to contact the study team at the first onset of a migraine. Upon arrival at Visit 2, individuals will be given an IV for blood draws. Once these the IV is in place, subjects will enter the MRI and be asked to stay very still. Scanning will occur for about 20 minutes, and then subjects will be given a Treximet tablet to combat their migraine. More scanning will follow Treximet administration. Some scans will have no stimulation, and others will apply a heat stimulus that subjects will rate using a pain scale. Seven 5-mL blood samples will be drawn throughout the duration of the MRI session. Both Visit 1 and Visit 2 will be compensated.

Conditions

Acute Migraine

Keywords

Acute Migraine; Treximet; Imaging; fMRI; Pain; Heat Stimulus

Study Design

• Observational Model Type: COHORT

Study Groups

Treximet

All migraine subjects will receive Treximet during a migraine episode at Visit 2.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Male or female (not pregnant or nursing)
• Age 18-65; with a focus on age 30-40 years
• Episodic migraine (experience migraine headache <14 days out of the month), with focus on left-sided pain
• Currently taking Treximet routinely for migraine treatment
• No significant medical history (No illnesses such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.)
• No significant medication history, except for migraine
• Weight, <285 pounds
• Not claustrophobic
• No contraindication to taking triptans

Exclusion Criteria

• Age <18 or > 65
• Significant medical problems (aside from pain before, during and after migraine episodes)
• Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.)
• Use of opioid medications
• Claustrophobia
• History of dermatological hypersensitivity in the facial area
• Pregnancy
• Sensory loss detected on Quantitative Sensory Testing at screening
• Significant alcohol history (ingestion of 5 or more glasses (> 40 oz) of alcohol per week)
• Metal implants of any type (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, etc.)
• Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could become heated up in the scanner, and potentially cause blistering or burning)
• Cardiac pacemakers
• Aneurysm clips and other vascular stents, filters, clips or other devices
• Prosthetic heart valves
• Other prostheses
• Neuro-stimulator devices
• Implanted infusion pumps
• Cochlear (ear) implants
• Ocular (eye) implants or known metal fragments in eyes
• Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)
• Other metallic surgical hardware in vital areas
• Any known allergic side effects to Treximet
• Use of any of the following medications:
• Monoamine Oxidase A- Inhibitors (Azilect, Eldepryl, Marplan, Nardil, Parnate, Zelapar)
• SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem, Symbyax, Sertraline/ Zoloft, Fluvoxamine/ Luvox
• SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor
• Triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/ Maxalt, eletriptan/ Relpax, almotriptan/ Axert
• Ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45, Sansert

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

Mclean Hospital

OTHER

Sponsor Role: lead

Responsible Party

David Borsook, MD, PhD

Senior Research Associate

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

David Borsook, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Mclean Hospital

Locations

Neuroimaging Center, McLean Hospital

Belmont, Massachusetts, United States

Countries

United States

Other Identifiers

400483

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2009-P-002689

Identifier Type: -

Identifier Source: org_study_id